A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 251 participants.

Also called NCT06441630

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 251 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06441630
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06441630. Randomized; double masking; primary purpose treatment. Start 2024-07-31 (actual); primary completion 2025-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
Condition
Essential Hypertension
Intervention (Drug)
AD-227A
Intervention (Drug)
AD-227B
Intervention (Drug)
AD-227C
Intervention (Drug)
Placebo of AD-227B
Intervention (Drug)
Placebo of AD-227C
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct06441630
Content hash
5cf7852b32d5c55e586561b110f0d3fd962cdf7d744aca9efdc1706ec261a2b2